The Meza ITP Study will be evaluating options for adults with Primary Immune Thrombocytopenia (ITP). Sign up for the WeConnect registry to be one of the first to be notified when the Meza ITP Study goes live!
Visit Takeda's Clinical Trials Transparency page to get in-depth information on all of Takeda's clinical research trials.
By joining WeConnect, you will be kept informed of trials that match your health needs so that you can have further conversations with your healthcare provider.
Primary Immune Thrombocytopenia (ITP) is a rare autoimmune condition that affects the blood's ability to clot properly. While ITP can be a lifelong condition, many people lead full, active lives with proper medical care and lifestyle adjustments.
Primary Immune Thrombocytopenia (also called idiopathic thrombocytopenic purpura) is a disorder where the immune system mistakenly attacks the body’s own platelets (cells that help stop bleeding). A low platelet count can lead to easy bruising, bleeding gums, or more serious complications in some cases.
ITP can occur at any age but is most commonly diagnosed in children and adults between 20 and 50 years old. In children, it often follows a viral infection and usually resolves on its own. In adults, it tends to be more chronic.
The exact cause of ITP isn’t fully understood. It’s classified as “primary” because it occurs on its own, without a clear underlying disease triggering it. However, certain factors may contribute to developing ITP:
While ITP is not inherited and cannot be transmitted from person to person, being aware of potential risk factors can help with early detection and treatment.
There is no single test for ITP, so diagnosis typically involves ruling out other causes of low platelet counts (thrombocytopenia). A healthcare provider may perform the following:
ITP is often a diagnosis of exclusion, meaning other causes must first be ruled out before a diagnosis is confirmed.
While ITP can be unpredictable, many people live well with the condition. Early diagnosis, close monitoring, and collaboration with a knowledgeable healthcare team can make a big difference.
Common symptoms may include:
Management may include:
It’s important for patients to stay connected with a hematologist and attend regular follow-up visits. Emotional support and advocacy groups can also help patients and families cope with the challenges of a chronic condition.
Research into ITP has progressed significantly over the past decade. Scientists are working every day to learn more about ITP. Clinical research is exploring new medicines that might improve health outcomes.
Your experience with ITP is valuable. Take the next step in supporting ITP research.
Sign up for our patient registry today. Together, we can make a difference.
Now, you can relax while we keep you updated with notifications about Takeda’s clinical trials that might be just the right fit for you.
We know you're interested in signing up for Takeda's WeConnect to get direct communication about Takeda clinical trials, but just in case you are looking for other ways to get involved – please review the information below.
BioLife Plasma Services is Takeda’s global plasma collection network and an industry leader in the collection of high-quality plasma that is processed into life-saving plasma-based therapies that benefit thousands of people every day.
Learn more about plasma donation and how to help people who require life-saving plasma-based therapies by donating your plasma.
Our goal is to be readily available to support clinicians and researchers in whatever way we can. We believe the best way to improve disease outcomes is through robust and open communication about the science and clinical evidence.
That’s why we love to hear from medical professionals—to hear your questions, to understand what you’re seeing in the clinic, and to discuss research.